Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,371 across all filing types
Latest filing 2024-12-19 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES FIRST PATIENT ENROLLED IN THE GLOBAL MULTICENTER PHASE IB CLINICAL TRIAL OF CS5001 (ROR1 ADC)
Regulatory Filings Classification · 1% confidence The document is a voluntary Hong Kong Exchange announcement regarding a clinical trial milestone (first patient enrolled) for CS5001. It is not an annual or interim financial report, earnings release, board change, share transaction, dividend notice, M&A or capital raising notice. It does not present detailed financial statements or summaries, nor does it attach a report for publication. As no specific category applies, it falls under the general regulatory announcements / fallback category (RNS).
2024-12-19 English
ANNOUNCEMENT ON RESULTS OF THE ISSUANCE OF THE 2024 FOURTH TRANCHE OF MEDIUM-TERM NOTES
Capital/Financing Update Classification · 1% confidence The document is an announcement under Hong Kong Listing Rules regarding the successful issuance of the 2024 fourth tranche of medium-term notes (debt financing). It details the issuance amount, terms, coupon rate, bookrunners, and underwriters, which clearly constitutes a financing activity update. This aligns directly with the Capital/Financing Update category (Code: CAP).
2024-12-12 English
VOLUNTARY ANNOUNCEMENT - CSTONE PRESENTS LATEST CLINICAL DATA ON CS5001 FOR ADVANCED LYMPHOMA AT THE 66TH ASH ANNUAL MEETING
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement made via the Hong Kong Exchange (HKEX) regarding the presentation of clinical data and an upcoming webcast, without any financial results, voting outcomes, management changes, or other specific corporate actions. It is not an earnings release, annual/interim report, or any other defined category. Therefore, it falls into the general “Regulatory Filings” (RNS) fallback category.
2024-12-09 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2024
Share Issue/Capital Change Classification · 1% confidence The document is an HKEX Form FF301 monthly return reporting detailed movements in the issuer’s share capital (authorised/registered share capital, issued shares, share options, treasury shares, etc.) under Chapter 19B of the Exchange Listing Rules. This is a routine regulatory submission disclosing capital structure changes and share issuances (even though there were no movements this month). It matches the description for “Share Issue/Capital Change” filings (SHA), which cover announcements and documents related to new share issues, stock splits, or other capital changes under listing rules.
2024-12-05 English
Monthly Return
Regulatory Filings Classification · 1% confidence The document is HKEX Form FF301, a Monthly Return for Equity Issuers and Hong Kong Depositary Receipts under Chapter 19B of the Exchange Listing Rules, detailing movements in registered/issued share capital and treasury shares. It is a periodic regulatory submission rather than an earnings release, director dealings, or other specific corporate action. It does not itself announce a corporate event but fulfills ongoing listing rule requirements. This fits the fallback “Regulatory Filings” category.
2024-12-02 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 1% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-11-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.